New combo therapy aims to tame rare blood cancer symptoms

NCT ID NCT05371964

Recruiting now Disease control Sponsor: Geron Corporation Source: ClinicalTrials.gov ↗

Summary

This early-stage study is testing whether adding a new drug called imetelstat to an existing medication (ruxolitinib) is safe and helpful for people with myelofibrosis, a rare bone marrow cancer. Researchers will enroll 36 patients to find the right dose and see if the combination reduces symptoms like fatigue and abdominal discomfort, and shrinks enlarged spleens. The goal is to better control the disease and improve quality of life for patients.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

City of Hope
RECRUITING

Duarte, California, 91010, United States
City of Hope
RECRUITING

Irvine, California, 92618, United States
Fred Hutchinson Cancer Center
RECRUITING

Seattle, Washington, 98109, United States
H. Lee Moffitt Cancer Center and Research Institute, Inc.
RECRUITING

Tampa, Florida, 33612, United States
Icahn School of Medicine at Mount Sinai
RECRUITING

New York, New York, 10029, United States
Texas Oncology
WITHDRAWN

Denison, Texas, 75020, United States
Texas Oncology
WITHDRAWN

Tyler, Texas, 75702, United States
University of Miami
RECRUITING

Coral Gables, Florida, 33146, United States

Conditions

Explore the condition pages connected to this study.

MYELOFIBROSIS